New obesity drug combo enters human safety trials
NCT ID NCT06916065
First seen Oct 31, 2025 · Last updated May 01, 2026 · Updated 23 times
Summary
This early-stage study tested the safety and tolerability of a new drug called eloralintide, given alone or with another weight-loss drug (tirzepatide), in 188 adults with overweight or obesity. Participants received weekly injections under the skin for up to 26 weeks. Researchers monitored side effects and measured how much drug got into the blood and how quickly it left the body.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBESITY are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Anaheim Clinical Trials, LLC
Anaheim, California, 92801, United States
-
Fortrea Clinical Research Unit
Daytona Beach, Florida, 32117, United States
-
Fortrea Clinical Research Unit
Dallas, Texas, 75247, United States
Conditions
Explore the condition pages connected to this study.